GSK-2894631A

CAS No. 2101626-26-8

GSK-2894631A ( HPGDS inhibitor 2 )

Catalog No. M23952 CAS No. 2101626-26-8

HPGDS inhibitor 2 is a potent, selective hematopoietic prostaglandin D synthase (h-pgds) inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 260 In Stock
10MG 410 In Stock
25MG 678 In Stock
50MG 954 In Stock
100MG 1287 In Stock
500MG 2574 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GSK-2894631A
  • Note
    Research use only, not for human use.
  • Brief Description
    HPGDS inhibitor 2 is a potent, selective hematopoietic prostaglandin D synthase (h-pgds) inhibitor.
  • Description
    HPGDS inhibitor 2 is a potent, selective hematopoietic prostaglandin D synthase (h-pgds) inhibitor, IC50 = 9.9 nm.
  • Synonyms
    HPGDS inhibitor 2
  • Pathway
    Immunology/Inflammation
  • Target
    PGE synthase
  • Recptor
    hPGDS
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2101626-26-8
  • Formula Weight
    378.4
  • Molecular Formula
    C20H24F2N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:130mg/ml(343.54mM)
  • SMILES
    FC(F)OC1=CC=C2C(N=CC(C(N[C@@H]3CC[C@@H](C(C)(C)O)CC3)=O)=C2)=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Rc A , Dnd A , Yd A , et al. The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure[J]. Bioorganic & Medicinal Chemistry, 2020, 28( 23).
molnova catalog
related products
  • Crisdesalazine

    Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro.

  • LY3031207

    A novel potent (IC50=910 ng/mL), highly selective microsomal prostaglandin E synthase 1 inhibitor (mPGES-1) for treatment of undisclosed indications.

  • Pizuglanstat

    Pizuglanstat is a potent, selective prostaglandin D synthase inhibitor.